Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype
- PMID: 23412770
- DOI: 10.1007/s10549-013-2442-0
Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype
Abstract
In epithelial-to-mesenchymal transition (EMT) epithelial cancer cells achieve mesenchymal features, essentially helping them to metastasize. There is some evidence that EMT could be increased in triple-negative (TNBC) or basal-like breast cancers, although more precise mechanisms considering e.g. EMT-regulating transcription factors are largely unknown. We assessed immunohistochemically vimentin (separately in in situ areas and in invasive cells) as an indicator of EMT, and also EMT-regulating transcription factors zeb1 (separately in stroma and tumour) and Sip1 (in nuclei and cytoplasm) in histological samples of 231 women with local or locally advanced invasive breast cancer. 51.1 % of patients had TNBC and 48.9 % oestrogen and progesterone receptor-positive and HER2 negative breast cancer. Basal-like breast cancers were defined as TNBC that also expressed epidermal growth factor receptor EGFR and/or cytokeratin 5/6. Vimentin expression in invasive cells was higher in TNBCs (p = 9 × 10(-12)) compared to non-TNBC tumours. Vimentin (p = 2 × 10(-6)), nuclear Sip1 (p = 0.035) and zeb1 in stroma (p = 0.013) were overexpressed in basal-like cancers compared to non-basal-like TNBCs. In non-TNBC group findings between studied markers and clinicopathological factors were rare. However, in TNBC cases, vimentin expression in invasive cells associated with poor differentiation (p = 0.00007), zeb1 expression in cancer cells with higher grade (p = 0.002), vascular invasion (p = 0.036) and larger T-class (p = 0.027), whereas stromal zeb1 associated with lymphatic vessel invasion (p = 0.036) and vascular invasion (p = 0.039). High nuclear Sip1 expression was prognostic for poor disease-free survival (p = 0.002) in the whole cohort. The current results emphasize the increased role of EMT in TNBC and especially in basal-like breast cancers. These observations also support the role of studied parameters in tumour progression.
Similar articles
-
Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.Hum Pathol. 2015 Sep;46(9):1267-74. doi: 10.1016/j.humpath.2015.05.010. Epub 2015 May 30. Hum Pathol. 2015. PMID: 26170011
-
Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.Pathology. 2012 Jun;44(4):303-12. doi: 10.1097/PAT.0b013e3283534bcb. Pathology. 2012. PMID: 22544210
-
ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.Breast Cancer Res. 2012 Nov 16;14(6):R148. doi: 10.1186/bcr3358. Breast Cancer Res. 2012. PMID: 23158001 Free PMC article.
-
What is the difference between triple-negative and basal breast cancers?Cancer J. 2010 Jan-Feb;16(1):12-6. doi: 10.1097/PPO.0b013e3181cf04be. Cancer J. 2010. PMID: 20164685 Review.
-
Metastatic triple-negative breast cancer.Clin Oncol (R Coll Radiol). 2011 Nov;23(9):587-600. doi: 10.1016/j.clon.2011.03.013. Epub 2011 Apr 23. Clin Oncol (R Coll Radiol). 2011. PMID: 21524569 Review.
Cited by
-
Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?Cancers (Basel). 2022 Feb 22;14(5):1101. doi: 10.3390/cancers14051101. Cancers (Basel). 2022. PMID: 35267409 Free PMC article. Review.
-
ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types.Nat Commun. 2016 Feb 15;7:10498. doi: 10.1038/ncomms10498. Nat Commun. 2016. PMID: 26876920 Free PMC article.
-
Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy.Cancer Sci. 2017 Jul;108(7):1520-1529. doi: 10.1111/cas.13274. Epub 2017 Jun 14. Cancer Sci. 2017. PMID: 28474753 Free PMC article.
-
A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming.Oncogene. 2022 Nov;41(47):5076-5091. doi: 10.1038/s41388-022-02497-2. Epub 2022 Oct 15. Oncogene. 2022. PMID: 36243802
-
Case report: Partial cystectomy for pheochromocytoma of the urinary bladder: A case report and review of literature.Front Cardiovasc Med. 2022 Dec 19;9:1092260. doi: 10.3389/fcvm.2022.1092260. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36601067 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous